|
|
Volumn 106, Issue 7, 2015, Pages 545-549
|
|
Biosimilars in Dermatology: Current Situation (Part I);Biosimilares en dermatología. Situación actual (parte i)
a
|
|
Author keywords
Adalimumab; Biologic; Biosimilar; Clinical trials; Etanercept; Infliximab; Interchangeability; Legislation; Psoriasis; Substitution
|
|
Indexed keywords
BIOSIMILAR AGENT;
GENERIC DRUG;
INFLIXIMAB;
ARTICLE;
DERMATOLOGY;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG INDICATION;
DRUG SAFETY;
EUROPEAN UNION;
HUMAN;
PSORIASIS;
CLINICAL TRIAL (TOPIC);
DRUG FORMULATION;
DRUG SUBSTITUTION;
ECONOMICS;
LEGISLATION AND JURISPRUDENCE;
METHODOLOGY;
PROCEDURES;
THERAPEUTIC EQUIVALENCE;
ANALYTIC METHOD;
BIOLOGICAL THERAPY;
CLINICAL ASSESSMENT;
CONCEPTUAL FRAMEWORK;
PHARMACEUTICAL CARE;
PHASE 1 CLINICAL TRIAL (TOPIC);
PUBLIC HEALTH SERVICE;
SHORT SURVEY;
TREATMENT INDICATION;
BIOSIMILAR PHARMACEUTICALS;
CLINICAL TRIALS AS TOPIC;
DRUG APPROVAL;
DRUG COMPOUNDING;
DRUG SUBSTITUTION;
DRUGS, GENERIC;
EUROPEAN UNION;
HUMANS;
INFLIXIMAB;
PSORIASIS;
RESEARCH DESIGN;
THERAPEUTIC EQUIVALENCY;
|
|
EID: 85044288397
PISSN: 00017310
EISSN: 15782190
Source Type: Journal
DOI: 10.1016/j.ad.2015.04.006 Document Type: Short Survey |
|
Times cited : (10)
|
|
References (14)
|
